scispace - formally typeset
P

Peter D. Schellinger

Researcher at Ruhr University Bochum

Publications -  262
Citations -  18189

Peter D. Schellinger is an academic researcher from Ruhr University Bochum. The author has contributed to research in topics: Stroke & Thrombolysis. The author has an hindex of 64, co-authored 240 publications receiving 15911 citations. Previous affiliations of Peter D. Schellinger include University Hospitals of the Ruhr-University of Bochum & Heidelberg University.

Papers
More filters
Journal ArticleDOI

Therapy of acute basilar artery occlusion: intraarterial thrombolysis alone vs bridging therapy.

TL;DR: Bridging therapy for acute BAO with intravenous abciximab and intraarterial rt-PA appears to be safe and yields higher recanalization and improved survival rates, as well as an overall improved chance for a better outcome.
Journal ArticleDOI

Medical Management vs Mechanical Thrombectomy for Mild Strokes: An International Multicenter Study and Systematic Review and Meta-analysis.

TL;DR: A multicenter study coupled with the meta-analysis suggests similar outcomes of MT and bMM in patients with stroke with mELVO, but no conclusions about treatment effect can be made.
Journal ArticleDOI

Neuroprotective effect of delayed moderate hypothermia after focal cerebral ischemia: an MRI study.

TL;DR: The results suggest that even delayed postischemic hypothermia can reduce the extent of infarct volume and brain edema after transient focal cerebral ischemia.
Journal ArticleDOI

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Götz Thomalla, +775 more
- 14 Nov 2020 - 
TL;DR: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care despite an increased risk of symptomatic intracranial haemorrhage.
Journal ArticleDOI

Thrombolytic Therapy Within 3 to 6 Hours After Onset of Ischemic Stroke Useful or Harmful

TL;DR: It appears unjustified to limit thrombolytic therapy to 3 hours, and better methods for patient selection are required; in particular, newer MRI techniques, such as diffusion- and perfusion-weighted imaging, can play a key role.